NO20062663L - Nukleinsyre som spesifikt binder bioaktivt ghrelin - Google Patents

Nukleinsyre som spesifikt binder bioaktivt ghrelin

Info

Publication number
NO20062663L
NO20062663L NO20062663A NO20062663A NO20062663L NO 20062663 L NO20062663 L NO 20062663L NO 20062663 A NO20062663 A NO 20062663A NO 20062663 A NO20062663 A NO 20062663A NO 20062663 L NO20062663 L NO 20062663L
Authority
NO
Norway
Prior art keywords
nucleic acid
specifically binds
bioactive ghrelin
binds bioactive
ghrelin
Prior art date
Application number
NO20062663A
Other languages
English (en)
Inventor
Sven Klussmann
Steffen Helmling
Christian Maasch
Klaus Buchner
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of NO20062663L publication Critical patent/NO20062663L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Det beskrives en nukleinsyre som spesifikt binder bioaktivt grelin og mer spesielt n-oktanoylgrelin, og dennes anvendelse for diagnose av grelimnedierte forstyrrelser og sykdommer.
NO20062663A 2003-11-10 2006-06-09 Nukleinsyre som spesifikt binder bioaktivt ghrelin NO20062663L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025743 2003-11-10
PCT/EP2004/012739 WO2005049828A1 (en) 2003-11-10 2004-11-10 Nucleic acids specifically binding bioactive ghrelin

Publications (1)

Publication Number Publication Date
NO20062663L true NO20062663L (no) 2006-08-09

Family

ID=34610046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062663A NO20062663L (no) 2003-11-10 2006-06-09 Nukleinsyre som spesifikt binder bioaktivt ghrelin

Country Status (19)

Country Link
US (2) US20070031840A1 (no)
EP (1) EP1682662A1 (no)
JP (1) JP4823067B2 (no)
KR (1) KR20060125743A (no)
CN (1) CN1894407A (no)
AP (1) AP2006003618A0 (no)
AU (1) AU2004291656A1 (no)
BR (1) BRPI0415872A (no)
CA (1) CA2544805A1 (no)
CR (1) CR8388A (no)
EA (1) EA009376B1 (no)
EC (1) ECSP066559A (no)
IL (1) IL175443A0 (no)
MA (1) MA28153A1 (no)
NO (1) NO20062663L (no)
OA (1) OA13282A (no)
TN (1) TNSN06132A1 (no)
WO (1) WO2005049828A1 (no)
ZA (1) ZA200603435B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251681A1 (en) * 2002-08-01 2004-02-23 Noxxon Pharma Ag Ghrelin binding nucleic acids
EP2290071B1 (en) * 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2115138A2 (en) * 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
CA2671294A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
CN101622348A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EP2268832A2 (en) * 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
JP2013509434A (ja) 2009-10-30 2013-03-14 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体アンタゴニストおよびインバースアゴニストならびにその使用方法
CA2824073A1 (en) * 2011-01-10 2012-07-19 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
CA2084987C (en) * 1990-06-11 2007-02-13 Larry Gold Nucleic acid ligands
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
WO1996034879A1 (en) * 1995-05-03 1996-11-07 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
AU2001259056A1 (en) * 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US20030211967A1 (en) * 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
JP2004514651A (ja) * 2000-05-30 2004-05-20 メルク　エンド　カムパニー　インコーポレーテッド グレリン類似体
AU2003251681A1 (en) * 2002-08-01 2004-02-23 Noxxon Pharma Ag Ghrelin binding nucleic acids
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
US20070031840A1 (en) 2007-02-08
JP4823067B2 (ja) 2011-11-24
IL175443A0 (en) 2006-09-05
CA2544805A1 (en) 2005-06-02
EP1682662A1 (en) 2006-07-26
CN1894407A (zh) 2007-01-10
ZA200603435B (en) 2007-06-27
EA200600735A1 (ru) 2006-10-27
OA13282A (en) 2007-01-31
US20100261291A1 (en) 2010-10-14
AU2004291656A1 (en) 2005-06-02
MA28153A1 (fr) 2006-09-01
KR20060125743A (ko) 2006-12-06
BRPI0415872A (pt) 2007-01-09
TNSN06132A1 (fr) 2007-11-15
AP2006003618A0 (en) 2006-06-30
JP2007513608A (ja) 2007-05-31
WO2005049828A1 (en) 2005-06-02
CR8388A (es) 2006-10-17
EA009376B1 (ru) 2007-12-28
ECSP066559A (no) 2006-11-24

Similar Documents

Publication Publication Date Title
NO20062663L (no) Nukleinsyre som spesifikt binder bioaktivt ghrelin
WO2005046603A3 (en) Pyridine compounds
NO20055381D0 (no) Enkel inkubasjon, multisting-endoskopisk sutursystem
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
DK1409459T3 (da) ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme.
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
NO20035496D0 (no) Substituerte sulfonamidforbindelser, fremgangsmåte for deres anvendelse sommedikament til behandling av CNS-forstyrrelser, overvekt og typeII-diabetes
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
WO2004113277A8 (en) Methods and compositions for treating amyloid-related diseases
WO2007075852A3 (en) Calcium channel antagonists
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
NO20044898L (no) Nye etonogestrel estere
ATE325124T1 (de) Ccr1-rezeptor-antagonisten zur behandlung u.a. demyelinisierender entzündlicher erkrankungen
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
BR0300119B1 (pt) composiÇço aquosa.
ITMO20020337A0 (it) Dispositivo per anastomosi.
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
NL1026716A1 (nl) Verbindingen.
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
DK1713438T3 (da) Medicinsk sæbe
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
WO2002086504A3 (en) Individualization of therapy with gastroesophageal reflux disease agents
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application